Inbred redirects here. For the 2011 British film, see Inbred (film).
Inbreeding is the production of offspring from the mating or breeding of individuals or organisms that are closely related genetically, in contrast to outcrossing, which refers to mating unrelated individuals.[1] By analogy, the term is used in human reproduction, but more commonly refers to the genetic disorders and other consequences that may arise from incestuous sexual relationships and consanguinity.
Inbreeding results in homozygosity, which can increase the chances of offspring being affected by recessive or deleterious traits.[2] This generally leads to a decreased biological fitness of a population[3][4] (called inbreeding depression), which is its ability to survive and reproduce. An individual who inherits such deleterious traits is referred to as inbred. The avoidance of such deleterious recessive alleles caused by inbreeding, via inbreeding avoidance mechanisms, is the main selective reason for outcrossing.[5][6] Crossbreeding between populations also often has positive effects on fitness-related traits.[7]
Inbreeding is a technique used in selective breeding. In livestock breeding, breeders may use inbreeding when, for example, trying to establish a new and desirable trait in the stock, but will need to watch for undesirable characteristics in offspring, which can then be eliminated through further selective breeding or culling. Inbreeding is used to reveal deleterious recessive alleles, which can then be eliminated through assortative breeding or through culling. In plant breeding, inbred lines are used as stocks for the creation of hybrid lines to make use of the effects of heterosis. Inbreeding in plants also occurs naturally in the form of self-pollination.
Offspring of biologically related persons are subject to the possible impact of inbreeding, such as congenital birth defects. The chances of such disorders is increased the closer the relationship of the biological parents. (See coefficient of inbreeding.) This is because such pairings increase the proportion of homozygous zygotes in the offspring, in particular deleterious recessive alleles, which produce such disorders.[8] (See inbreeding depression.) Because most recessive alleles are rare in populations, it is unlikely that two unrelated marriage partners will both be carriers of the alleles. However, because close relatives share a large fraction of their alleles, the probability that any such deleterious allele is inherited from the common ancestor through both parents is increased dramatically. Contrary to common belief, inbreeding does not in itself alter allele frequencies, but rather increases the relative proportion of homozygotes to heterozygotes. However, because the increased proportion of deleterious homozygotes exposes the allele to natural selection, in the long run its frequency decreases more rapidly in inbred population. In the short term, incestuous reproduction is expected to produce increases in spontaneous abortions of zygotes, perinatal deaths, and postnatal offspring with birth defects.[9] The advantages of inbreeding may be the result of a tendency to preserve the structures of alleles interacting at different loci that have been adapted together by a common selective history.[10]
Malformations or harmful traits can stay within a population due to a high homozygosity rate and it will cause a population to become fixed for certain traits, like having too many bones in an area, like the vertebral column in wolves on Isle Royale or having cranial abnormalities in Northern elephant seals, where their cranial bone length in the lower mandibular tooth row has changed. Having a high homozygosity rate is bad for a population because it will unmask recessive deleterious alleles generated by mutations, reduce heterozygote advantage, and it is detrimental to the survival of small, endangered animal populations.[11] When there are deleterious recessive alleles in a population it can cause inbreeding depression. The authors think that it is possible that the severity of inbreeding depression can be diminished if natural selection can purge such alleles from populations during inbreeding.[12] If inbreeding depression can be diminished by natural selection than some traits, harmful or not, can be reduced and change the future outlook on a small, endangered populations.
There may also be other deleterious effects besides those caused by recessive diseases. Thus, similar immune systems may be more vulnerable to infectious diseases (see Major histocompatibility complex and sexual selection).[13]
Inbreeding history of the population should also be considered when discussing the variation in the severity of inbreeding depression between and within species. With persistent inbreeding, there is evidence that shows inbreeding depression becoming less severe. This is associated with the unmasking and eliminating of severely deleterious recessive alleles. It is not likely, though, that eliminating can be so complete that inbreeding depression is only a temporary phenomenon. Eliminating slightly deleterious mutations through inbreeding under moderate selection is not as effective. Fixation of alleles most likely occurs through Mullers Ratchet, when an asexual populations genomes accumulate deleterious mutations that are irreversible.[14]
Autosomal recessive disorders occur in individuals who have two copies of the gene for a particular recessive genetic mutation.[15] Except in certain rare circumstances, such as new mutations or uniparental disomy, both parents of an individual with such a disorder will be carriers of the gene. These carriers do not display any signs of the mutation and may be unaware that they carry the mutated gene. Since relatives share a higher proportion of their genes than do unrelated people, it is more likely that related parents will both be carriers of the same recessive gene, and therefore their children are at a higher risk of a genetic disorder. The extent to which the risk increases depends on the degree of genetic relationship between the parents: The risk is greater when the parents are close relatives and lower for relationships between more distant relatives, such as second cousins, though still greater than for the general population.[16] A study has provided the evidence for inbreeding depression on cognitive abilities among children, with high frequency of mental retardation among offspring in proportion to their increasing inbreeding coefficients.[17]
Children of parent-child or sibling-sibling unions are at increased risk compared to cousin-cousin unions.[18]
Follow this link:
Stem Cells Therapy
- BIORESTORATIVE THERAPIES, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-K) - Marketscreener.com - March 29th, 2023
- Induced Pluripotent Stem Cell for the Study and Treatment of ... - Hindawi - December 3rd, 2022
- What Happens When Everyone Realises We Can Live Much Longer? We May Find Out As Soon As 2025 - Forbes - December 3rd, 2022
- INTERNATIONAL STEM CELL CORP Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q) - Marketscreener.com - November 17th, 2022
- 3D Cell Culture Market stands at revenue of US$ 1.15 Bn in 2022, and is predicted to surge at a CAGR of 9.8% to hit worth of US$ 2.67 Bn during... - November 17th, 2022
- YUBO INTERNATIONAL BIOTECH LTD Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q) - Marketscreener.com - November 17th, 2022
- ACTINIUM PHARMACEUTICALS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION (form 10-Q) - Marketscreener.com - November 17th, 2022
- Top 10 Best Stem Cell Supplement Brands - Healthtrends - June 26th, 2022
- How Does Stem Cell Therapy Work and What Are the Risks? | ISCRM - June 26th, 2022
- Stem Cell Wellness Kit - June 26th, 2022
- Kangstem Biotech withdraws trial application for stem cell-based osteoarthritis treatment - KBR - June 26th, 2022
- Global Human Embryonic Stem Cell Market to be Driven by the Rapid Technological Advancements in the Forecast Period of 2022-2027 Designer Women -... - June 26th, 2022
- Sana Biotechnology Announces Multiple Preclinical Data Presentations to Showcase Its Hypoimmune Platform, Including in Type 1 Diabetes, at the... - June 26th, 2022
- Efficient terminal erythroid differentiation requires the APC/C cofactor Cdh1 to limit replicative stress in erythroblasts | Scientific Reports -... - June 26th, 2022
- Propanc Biopharma's CSO Hails Dostarlimab's Impressive Results Whilst Acknowledging More Work to Be Done in the Fight Against Cancer - Business Wire - June 26th, 2022
- Precision BioSciences Announces In Vivo Gene Editing Collaboration with Novartis to Develop Potentially Curative Treatment for Disorders Including... - June 26th, 2022
- 10 Years of Immunotherapy: Advances, Innovations, and Better Patient Outcomes - Targeted Oncology - June 26th, 2022
- Embryonic Stem Cell Research: An Ethical Dilemma - January 30th, 2022
- Skeletal Muscle Cell Induction from Pluripotent Stem Cells - January 30th, 2022
- mRNA COVID-19 Vaccine Effectiveness in the Immunocompromised - Medscape - January 30th, 2022
- MaaT Pharma Announces Positive Interim Engraftment Data for Oral Formulation MaaT033 Allowing Early Termination of Phase 1b CIMON Study - Business... - January 30th, 2022
- European Commission Approves Merck's KEYTRUDA (pembrolizumab) as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma (RCC) Following... - January 30th, 2022
- Targeted Therapy Innovator Foresees New Paradigms in Breast Cancer - OncLive - January 30th, 2022
- Global Circulating Tumor Cells (CTC) Market Growing Demand, Future Trends, Competitive Regions and Forecast 2021 to 2027 The Oxford Spokesman - The... - January 30th, 2022
- Adipose derived mesenchymal stem cell secretome formulation as a biotherapeutic to inhibit growth of drug resistant triple negative breast cancer |... - December 8th, 2021
- All at-risk TN-bound travellers test Covid negative - The New Indian Express - December 8th, 2021
- Good Stocks To Invest In Right Now? 4 Health Care Stocks To Check Out - FW Business - December 8th, 2021
- Pandemic lockdown declined emotional well-being for adults with hearing, vision loss: Study - ETHealthworld.com - December 8th, 2021
- Impact of microbial contamination of haematopoietic stem cells on post-transplant outcomes: A retrospective study from tertiary care centre in India -... - August 17th, 2021
- Longeveron: Time to Buy the Di - GuruFocus.com - August 17th, 2021
- The latest on the Covid-19 pandemic in the US: Live updates - CNN - August 17th, 2021
- How this Holocaust refugee beat Covid-19 against all odds J. - The Jewish News of Northern California - August 17th, 2021
- Trade-offs among transport, support, and storage in xylem from shrubs in a semiarid chaparral environment tested with structural equation modeling -... - August 17th, 2021
- Oklahoma 10-year-old in remission after being diagnosed with rare form of leukemia 2 years ago - KFOR Oklahoma City - July 21st, 2021
- Covid: There's a serious problem with how we are testing people for the virus Neale Hanvey MP - The Scotsman - July 21st, 2021
- Profilin 1 Protein and Its Implications for Cancers - Cancer Network - July 21st, 2021
- Homing Technology Delivers Therapy to Cancerous Bone - The Scientist - July 21st, 2021
- Developmental Interest in Allogeneic PlacentaDerived Cell Therapies Expands - OncLive - July 21st, 2021
- Triple negative breast cancer and non-small cell lung cancer: Clinical challenges and nano-formulation approaches - DocWire News - July 21st, 2021
- The World's First Lab-Grown Foie Gras Could Solve This Major Concern - Mashed - July 21st, 2021
- KEYTRUDA (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as a Single Agent After Surgery Showed Statistically Significant Event-Free... - July 21st, 2021
- Human Mesenchymal Stem Cells (hMSC) Market Size 2021 | Global Trends, Business Overview, Challenges, Opportunities and Forecast to 2027 The Bisouv... - March 3rd, 2021
- [Full text] An Update on the Molecular Pathology of Metaplastic Breast Cancer | BCTT - Dove Medical Press - March 3rd, 2021
- 4D Pharma Appointments Paul Maier to the Board as Non-Executive Director - Business Wire - March 3rd, 2021
- Investigative Interventions Gain Ground in GVHD - OncLive - March 3rd, 2021
- Combination Regimens for Multiple Myeloma Show Efficacy in the Transplant-Ineligible Population, According to Dingli - Targeted Oncology - March 3rd, 2021
- Martin Makes Sense of the Rapidly Evolving MCL Treatment Paradigm - OncLive - March 3rd, 2021
- Hoth Therapeutics Expands License Agreement to Include Innovative Cancer and Anaphylactic Treatment - BioSpace - March 3rd, 2021
- Health Matters; Inflammation with Dr. Baumgartner [PODCAST] - WJON News - February 14th, 2021
- G1 Therapeutics gains first FDA nod with myelopreservation therapy Cosela | 2021-02-12 - BioWorld Online - February 14th, 2021
- Kris Gopalakrishnan on innovation - Fortune India - February 14th, 2021
- Change is coming, and at an ever-accelerating pace - Al Jazeera English - January 12th, 2021
- MCL Landscape Adapts to Changes After CAR T-Cell Therapy Approval - OncLive - January 9th, 2021
- 5 questions facing gene therapy in 2021 - BioPharma Dive - January 9th, 2021
- RNA molecules are masters of their own destiny - MIT News - January 9th, 2021
- Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market: Industry Analysis and Forecast (2019-2026): By indication type, treatment type,... - January 9th, 2021
- Harpoon Therapeutics : Clin Cancer Res 2021; OnlineFirst version Jan 6, 2021 - Marketscreener.com - January 9th, 2021
- Synthetic lethality across normal tissues is strongly associated with cancer risk, onset, and tumor suppressor specificity - Science Advances - January 5th, 2021
- Versiti Blood Centers and Noodles & Company Serve Up Thanks to Blood Donors - PRNewswire - January 5th, 2021
- January 2021: 2020 Papers of the Year - Environmental Factor Newsletter - January 5th, 2021
- Ozone in the air is bad for birds - Massive Science - January 5th, 2021
- How good are the COVID-19 vaccines? - Massive Science - January 5th, 2021
- Stem cells from cord blood can now be used across many conditions: Mayur Abhaya, MD & CEO, LifeCell Internat.. - ETHealthworld.com - December 28th, 2020
- Allogeneic SCT Benefits Children and Adolescents With Relapsed Anaplastic Large Cell Lymphoma - OncLive - December 28th, 2020
- CalvinAyre.com's most read life stories of 2020 - CalvinAyre.com - December 28th, 2020
- Coronavirus | Over 6,000 travellers from U.K. traced across States - The Hindu - December 28th, 2020
- Exosomes act as messengers and decoys to save healthy cells from viral infection - Massive Science - December 28th, 2020
- Celtics adjust to two-game series designed to reduce team travel - The Boston Globe - December 28th, 2020
- Experts Reflect on Most Impactful FDA Moves of 2020 in Solid Tumors, Hematologic Malignancies - Targeted Oncology - December 28th, 2020
- FDA Resumes eIND Approval for Severe-to-Critical COVID-19 Patients Use of Vyrologix (leronlimab) Following Full Enrollment in CytoDyn's Phase 3 Trial... - December 28th, 2020
- Magenta Therapeutics Announces Commencement of First Phase 2 Clinical Trial of MGTA-145 for Stem Cell Mobilization, Oral Presentation of MGTA-145... - December 12th, 2020
- Daratumumab Regimen Shows Promise in Transplant-Eligible Patients With Newly Diagnosed Myeloma - Targeted Oncology - December 12th, 2020
- HSCT Found Potentially Curative for Some T-Cell Lymphoma Patients - Cancer Therapy Advisor - December 12th, 2020
- Researchers Trace the Origin of Blood Cancer to Early Childhood, Decades before Diagnosis - Yahoo Finance - December 12th, 2020
- ALLO-715, Off-the-Shelf CAR T-Cell Therapy, Produces Early Promise in Multiple Myeloma - Cancer Network - December 12th, 2020
- BeiGene Announces the Approval in China of BLINCYTO (Blinatumomab) for Injection for Adult Patients with Relapsed or Refractory B-Cell Precursor Acute... - December 12th, 2020
- Flintshire youngster goes the extra mile to raise funds for Lymphoma Action | The Leader - LeaderLive - December 12th, 2020
- Meat-Tech Agrees to Acquire Cultured Fat Pioneer 'Peace of Meat' - PRNewswire - December 12th, 2020
- Stem Cell Manufacturing Market Size, Overview with Detailed Analysis, Competitive landscape, Forecast to 2027 - Cheshire Media - December 12th, 2020
- Rocket Pharmaceuticals Presents Positive Clinical Data from its Fanconi Anemia and Leukocyte Adhesion Deficiency-I Programs at the 62nd American... - December 12th, 2020